These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 38003437)
21. IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis. Wang X; Kaiser H; Kvist-Hansen A; McCauley BD; Skov L; Hansen PR; Becker C Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008981 [TBL] [Abstract][Full Text] [Related]
22. Epidermal expression of interleukin-6 and tumour necrosis factor-alpha in normal and immunoinflammatory skin states in humans. Oxholm A APMIS Suppl; 1992; 24():1-32. PubMed ID: 1567657 [TBL] [Abstract][Full Text] [Related]
23. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients. Liu Y; Qin G; Meng Z; Du T; Wang X; Tang Y; Cao J Inflammopharmacology; 2019 Feb; 27(1):57-66. PubMed ID: 30242748 [TBL] [Abstract][Full Text] [Related]
24. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study. Schett G; Chen W; Gao S; Chakravarty SD; Shawi M; Lavie F; Zimmermann M; Sharaf M; Coates LC; Siebert S Arthritis Res Ther; 2023 Aug; 25(1):150. PubMed ID: 37587493 [TBL] [Abstract][Full Text] [Related]
25. Observational study on Swedish plaque psoriasis patients receiving narrowband-UVB treatment show decreased S100A8/A9 protein and gene expression levels in lesional psoriasis skin but no effect on S100A8/A9 protein levels in serum. Duvetorp A; Söderman J; Assarsson M; Skarstedt M; Svensson Å; Seifert O PLoS One; 2019; 14(3):e0213344. PubMed ID: 30865695 [TBL] [Abstract][Full Text] [Related]
26. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. Kreuter A; Hyun J; Skrygan M; Sommer A; Bastian A; Altmeyer P; Gambichler T Br J Dermatol; 2006 Sep; 155(3):600-7. PubMed ID: 16911288 [TBL] [Abstract][Full Text] [Related]
27. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. Sofen H; Smith S; Matheson RT; Leonardi CL; Calderon C; Brodmerkel C; Li K; Campbell K; Marciniak SJ; Wasfi Y; Wang Y; Szapary P; Krueger JG J Allergy Clin Immunol; 2014 Apr; 133(4):1032-40. PubMed ID: 24679469 [TBL] [Abstract][Full Text] [Related]
28. Infliximab induces downregulation of the IL-12/IL-23 axis in 6-sulfo-LacNac (slan)+ dendritic cells and macrophages. Brunner PM; Koszik F; Reininger B; Kalb ML; Bauer W; Stingl G J Allergy Clin Immunol; 2013 Nov; 132(5):1184-1193.e8. PubMed ID: 23890755 [TBL] [Abstract][Full Text] [Related]
29. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. Nomura I; Goleva E; Howell MD; Hamid QA; Ong PY; Hall CF; Darst MA; Gao B; Boguniewicz M; Travers JB; Leung DY J Immunol; 2003 Sep; 171(6):3262-9. PubMed ID: 12960356 [TBL] [Abstract][Full Text] [Related]
30. Losartan ointment attenuates imiquimod-induced psoriasis-like inflammation. Shokrian Zeini M; Haddadi NS; Shayan M; Shokrian Zeini M; Kazemi K; Solaimanian S; Abdollahifar MA; Hedayatyanfard K; Dehpour AR Int Immunopharmacol; 2021 Nov; 100():108160. PubMed ID: 34583123 [TBL] [Abstract][Full Text] [Related]
31. Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study. Onsun N; Akaslan TÇ; Sallahoglu K; Gülcan AS; Bulut H; Yabacı A J Dermatolog Treat; 2022 May; 33(3):1727-1732. PubMed ID: 33704001 [TBL] [Abstract][Full Text] [Related]
32. Association between several immune response-related genes and the effectiveness of biological treatments in patients with moderate-to-severe psoriasis. Loras A; Gil-Barrachina M; Hernando B; Perez-Pastor G; Martinez-Domenech A; Mahiques L; Pitarch G; Valcuende-Cavero F; Ballester-Sanchez R; Marques-Torrejon MA; Martinez-Cadenas C Exp Dermatol; 2024 Jan; 33(1):e15003. PubMed ID: 38284189 [TBL] [Abstract][Full Text] [Related]
33. Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling. Johnston A; Guzman AM; Swindell WR; Wang F; Kang S; Gudjonsson JE Br J Dermatol; 2014 Jul; 171(1):97-107. PubMed ID: 24601997 [TBL] [Abstract][Full Text] [Related]
34. [Effect of fire needling on imiquimod induced psoriasis-like lesion and STAT3 pathway in mice]. Feng F; Wang Y; Zhao JX; Di TT; Meng YJ; Chen ZX; Qi C; Hu XQ; Wang YZ; Li P Zhongguo Zhen Jiu; 2022 May; 42(5):541-8. PubMed ID: 35543945 [TBL] [Abstract][Full Text] [Related]
35. Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. Jansen PA; Rodijk-Olthuis D; Hollox EJ; Kamsteeg M; Tjabringa GS; de Jongh GJ; van Vlijmen-Willems IM; Bergboer JG; van Rossum MM; de Jong EM; den Heijer M; Evers AW; Bergers M; Armour JA; Zeeuwen PL; Schalkwijk J PLoS One; 2009; 4(3):e4725. PubMed ID: 19266104 [TBL] [Abstract][Full Text] [Related]
36. Association of disease severity with IL-1 levels in methotrexate-treated psoriasis patients. Tamilselvi E; Haripriya D; Hemamalini M; Pushpa G; Swapna S Scand J Immunol; 2013 Dec; 78(6):545-53. PubMed ID: 24283773 [TBL] [Abstract][Full Text] [Related]
37. Expression of miR-135b in Psoriatic Skin and Its Association with Disease Improvement. Chicharro P; Rodríguez-Jiménez P; Llamas-Velasco M; Montes N; Sanz-García A; Cibrian D; Vara A; Gómez MJ; Jiménez-Fernández M; Martínez-Fleta P; Sánchez-García I; Lozano-Prieto M; Triviño JC; Miñambres R; Sánchez-Madrid F; de la Fuente H; Dauden E Cells; 2020 Jul; 9(7):. PubMed ID: 32630692 [TBL] [Abstract][Full Text] [Related]
38. Immune response in human chromoblastomycosis and eumycetoma - focusing on human interleukin-17A, interferon-gamma, tumour necrosis factor-alpha, interleukin-1 beta and human beta-defensin-2. Leeyaphan C; Hau C; Takeoka S; Tada Y; Bunyaratavej S; Pattanaprichakul P; Sitthinamsuwan P; Chaiprasert A; Sasajima Y; Makimura K; Watanabe S Mycoses; 2016 Dec; 59(12):751-756. PubMed ID: 27402133 [TBL] [Abstract][Full Text] [Related]
39. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents. Shibuya T; Honma M; Iinuma S; Iwasaki T; Takahashi H; Ishida-Yamamoto A J Dermatol; 2018 Jun; 45(6):710-714. PubMed ID: 29655215 [TBL] [Abstract][Full Text] [Related]
40. Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy. Markham T; Mathews C; Rogers S; Mullan R; Bresnihan B; Fitzgerald O; Veale DJ; Fearon U Br J Dermatol; 2006 Dec; 155(6):1191-6. PubMed ID: 17107388 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]